Literature DB >> 23223356

SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease.

Christine Rivat1, Claire Booth, Maria Alonso-Ferrero, Michael Blundell, Neil J Sebire, Adrian J Thrasher, H Bobby Gaspar.   

Abstract

X-linked lymphoproliferative disease (XLP1) arises from mutations in the gene encoding SLAM-associated protein (SAP) and leads to abnormalities of NKT-cell development, NK-cell cytotoxicity, and T-dependent humoral function. Curative treatment is limited to allogeneic hematopoietic stem cell (HSC) transplantation. We tested whether HSC gene therapy could correct the multilineage defects seen in SAP(-/-) mice. SAP(-/-) murine HSCs were transduced with lentiviral vectors containing either SAP or reporter gene before transplantation into irradiated recipients. NKT-cell development was significantly higher and NK-cell cytotoxicity restored to wild-type levels in mice receiving the SAP vector in comparison to control mice. Baseline immunoglobulin levels were significantly increased and T-dependent humoral responses to NP-CGG, including germinal center formation, were restored in SAP-transduced mice.We demonstrate for the first time that HSC gene transfer corrects the cellular and humoral defects in SAP(-/-) mice providing proof of concept for gene therapy in XLP1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223356      PMCID: PMC3779401          DOI: 10.1182/blood-2012-07-445858

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  SAP controls T cell responses to virus and terminal differentiation of TH2 cells.

Authors:  C Wu; K B Nguyen; G C Pien; N Wang; C Gullo; D Howie; M R Sosa; M J Edwards; P Borrow; A R Satoskar; A H Sharpe; C A Biron; C Terhorst
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP.

Authors:  M J Czar; E N Kersh; L A Mijares; G Lanier; J Lewis; G Yap; A Chen; A Sher; C S Duckett; R Ahmed; P L Schwartzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

3.  Impaired Ig class switch in mice deficient for the X-linked lymphoproliferative disease gene Sap.

Authors:  Umaima Al-Alem; Cuiling Li; Nathalie Forey; Francis Relouzat; Marie-Claude Fondanèche; Sean V Tavtigian; Zhao-Qi Wang; Sylvain Latour; Luo Yin
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

4.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

Review 5.  X-linked lymphoproliferative disease: twenty-five years after the discovery.

Authors:  T A Seemayer; T G Gross; R M Egeler; S J Pirruccello; J R Davis; C M Kelly; M Okano; A Lanyi; J Sumegi
Journal:  Pediatr Res       Date:  1995-10       Impact factor: 3.756

6.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.

Authors:  K E Nichols; D P Harkin; S Levitz; M Krainer; K A Kolquist; C Genovese; A Bernard; M Ferguson; L Zuo; E Snyder; A J Buckler; C Wise; J Ashley; M Lovett; M B Valentine; A T Look; W Gerald; D E Housman; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

7.  Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry.

Authors:  T G Gross; A H Filipovich; M E Conley; E Pracher; K Schmiegelow; J D Verdirame; M Vowels; L L Williams; T A Seemayer
Journal:  Bone Marrow Transplant       Date:  1996-05       Impact factor: 5.483

8.  The β-globin locus control region in combination with the EF1α short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity.

Authors:  Claudia A Montiel-Equihua; Lin Zhang; Sean Knight; Heba Saadeh; Simone Scholz; Marlene Carmo; Maria E Alonso-Ferrero; Michael P Blundell; Aiste Monkeviciute; Reiner Schulz; Mary Collins; Yasuhiro Takeuchi; Manfred Schmidt; Lynette Fairbanks; Michael Antoniou; Adrian J Thrasher; H Bobby Gaspar
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

9.  Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells.

Authors:  Cindy S Ma; Nathan J Hare; Kim E Nichols; Loic Dupré; Grazia Andolfi; Maria-Grazia Roncarolo; Stephen Adelstein; Philip D Hodgkin; Stuart G Tangye
Journal:  J Clin Invest       Date:  2005-03-03       Impact factor: 14.808

10.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.

Authors:  J Sayos; C Wu; M Morra; N Wang; X Zhang; D Allen; S van Schaik; L Notarangelo; R Geha; M G Roncarolo; H Oettgen; J E De Vries; G Aversa; C Terhorst
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

View more
  17 in total

Review 1.  Evolving Gene Therapy in Primary Immunodeficiency.

Authors:  Adrian J Thrasher; David A Williams
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

Review 2.  Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.

Authors:  Fabio Candotti
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

3.  Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP.

Authors:  Benjamin C Houghton; Neelam Panchal; Simone A Haas; Kay O Chmielewski; Markus Hildenbeutel; Thomas Whittaker; Claudio Mussolino; Toni Cathomen; Adrian J Thrasher; Claire Booth
Journal:  Front Genome Ed       Date:  2022-05-23

Review 4.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

Review 5.  Lentiviral vectors for the treatment of primary immunodeficiencies.

Authors:  Giada Farinelli; Valentina Capo; Samantha Scaramuzza; Alessandro Aiuti
Journal:  J Inherit Metab Dis       Date:  2014-03-12       Impact factor: 4.982

Review 6.  Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning.

Authors:  Elena Sieni; Valentina Cetica; Yvonne Hackmann; Maria Luisa Coniglio; Martina Da Ros; Benedetta Ciambotti; Daniela Pende; Gillian Griffiths; Maurizio Aricò
Journal:  Front Immunol       Date:  2014-04-16       Impact factor: 7.561

7.  Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency.

Authors:  Marlene Carmo; Kimberly A Risma; Paritha Arumugam; Swati Tiwari; Adrianne E Hontz; Claudia A Montiel-Equihua; Maria E Alonso-Ferrero; Michael P Blundell; Axel Schambach; Christopher Baum; Punam Malik; Adrian J Thrasher; Michael B Jordan; H Bobby Gaspar
Journal:  Mol Ther       Date:  2014-12-19       Impact factor: 11.454

Review 8.  Gene therapy for primary immune deficiencies: a Canadian perspective.

Authors:  Xiaobai Xu; Chetankumar S Tailor; Eyal Grunebaum
Journal:  Allergy Asthma Clin Immunol       Date:  2017-02-27       Impact factor: 3.406

Review 9.  Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1.

Authors:  Suresh Velnati; Sara Centonze; Federico Girivetto; Gianluca Baldanzi
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

Review 10.  Advances of gene therapy for primary immunodeficiencies.

Authors:  Fabio Candotti
Journal:  F1000Res       Date:  2016-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.